Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study

R. Petrioli; A. Pascucci; R. Conca; G. Chiriaco; E. Francini; G. Bargagli; A. I. Fiaschi; A. Manganelli; G. De Rubertis; G. Barbanti; R. Ponchietti; G. Francini

doi:10.1038/bjc.2011.5

Back

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study

Journal article

Peer reviewed

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study

R. Petrioli, A. Pascucci, R. Conca, G. Chiriaco, E. Francini, G. Bargagli, A. I. Fiaschi, A. Manganelli, G. De Rubertis, G. Barbanti, …

British journal of cancer, Vol.104(4), pp.613-619

02/15/2011

DOI: 10.1038/bjc.2011.5

PMID: 21285986

Files and links (1)

url

https://doi.org/10.1038/bjc.2011.5View

Published (Version of record) Open Access

Abstract

BACKGROUND: This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients. MATERIALS AND METHODS: Patients were randomly assigned to D 30 mgm(-2) as intravenous infusion (i.v.) and EPI 30 mgm(-2) i.v. every week (D/EPI arm), or D 70 mgm(-2) i.v. every 3 weeks and oral P 5 mg twice daily (D/P arm). Chemotherapy was administered until disease progression or unacceptable toxicity. RESULTS: A total of 72 patients were enrolled in the study and randomly assigned to treatment: 37 to D/EPI and 35 to D/P. The median progression-free survival (PFS) was 11.1 months (95% CI 9.2-12.6 months) in the D/EPI arm and 7.7 months (95% CI 5.7-9.4 months) in the D/P arm (P = 0.0002). The median survival was 27.3 months (95% CI 22.1-30.8 months) in the D/EPI arm and 19.8 months (95% CI 14.4-24.8 months) in the D/P arm (P = 0.003). Both regimens were generally well tolerated. CONCLUSION: The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to superior PFS than the treatment with 3-weekly D and oral P. British Journal of Cancer (2011) 104, 613-619. doi:10.1038/bjc.2011.5 www.bjcancer.com Published online 1 February 2011 (C) 2011 Cancer Research UK

Life Sciences & Biomedicine

Oncology

Science & Technology

Details

Title: Subtitle: Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
Creators: R. Petrioli - University of Siena
A. Pascucci - University of Siena
R. Conca - University of Siena
G. Chiriaco - University of Siena
E. Francini - University of Siena
G. Bargagli - University of Siena
A. I. Fiaschi - University of Siena
A. Manganelli - University of Siena
G. De Rubertis - University of Siena
G. Barbanti - University of Siena
R. Ponchietti - University of Siena
G. Francini - University of Siena
Resource Type: Journal article
Publication Details: British journal of cancer, Vol.104(4), pp.613-619
DOI: 10.1038/bjc.2011.5
PMID: 21285986
ISSN: 0007-0920
eISSN: 1532-1827
Publisher: Springer Nature
Number of pages: 7
Language: English
Date published: 02/15/2011
Academic Unit: Internal Medicine
Record Identifier: 9985221145902771

Metrics

1 Record Views

11 Times Cited - Web of Science